alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2023063EN.01004402.xml

| 20.2.2023 | EN | Official Journal of the European Union | C 63/44 |
| --- | --- | --- | --- |

20.2.2023

EN

Official Journal of the European Union

C 63/44

---

Judgment of the General Court of 14 December 2022 — Esedra v Parliament

(Case T-46/22) (1)

(Public service contracts - Tender procedure - Full management of the Parliament’s early childhood centre in Brussels - Rejection of a tenderer’s tender - Abnormally low tender - Compliance of a tender with the conditions laid down in the specifications - Obligation to state reasons - Manifest errors of assessment)

(2023/C 63/56)

Language of the case: French

Parties

Applicant: Esedra (Brussels, Belgium) (represented by: M. Vastmans, lawyer)

Defendant: European Parliament (represented by: M. Pencheva and M. Kazek, acting as Agents)

Re:

By its action, the applicant seeks, first, on the basis of Article 263 TFEU, annulment of the decision of the European Parliament of 26 November 2021, entitled ‘Procédure de passation de marché PE PERS 2021 027 — Gestion complète de la structure d’accueil petite enfance du Parlement européen à Bruxelles, sise rue Wayenberg’(Procurement procedure PE PERS 2021 027 — Full management of the European Parliament’s early childhood centre in Brussels, located on Rue Wayenberg), rejecting the tender submitted by it in the context of the call for tenders and awarding the contract to another tenderer, and, second, on the basis of Article 268 TFEU, compensation for the damage which it has suffered as a result of that decision.

Operative part of the judgment

The Court:

| 1. | Dismisses the action; |
| --- | --- |

1.

Dismisses the action;

| 2. | Orders Esedra to bear its own costs and to pay the costs incurred by the European Parliament, including those relating to the proceedings for interim relief. |
| --- | --- |

2.

Orders Esedra to bear its own costs and to pay the costs incurred by the European Parliament, including those relating to the proceedings for interim relief.

---

(1)  OJ C 109, 7.3.2022.

---
EX-10.2





 Exhibit 10.2 

July 1, 2021 
 LETTER AGREEMENT 

Logan Ridge Finance Corporation (the “Company”) 

650 Madison Avenue, 23rd Floor 
 New York, NY 10022 

Re: Fee Waiver Agreement 
 This Letter Agreement documents the
agreement by Mount Logan Management LLC (the “Adviser”) to waive certain incentive fees payable or paid by the Company pursuant to the Investment Advisory Agreement between the Company and the Adviser dated July 1, 2021
(the “Advisory Agreement”). 
 For a period of two years beginning on July 1, 2021, the Adviser hereby agrees to waive and/or
reimburse fees payable or paid by the Company pursuant to the Advisory Agreement in an amount equal to the aggregate amount that capital gains incentive fees exceed capital gains incentive fees that would have been paid by the Company pursuant to
the Investment Advisory Agreement between the Company and Capitala Investment Advisors, LLC dated September 24, 2013. This waiver will be accrued annually on a cumulative basis and, to the extent required, any fees will be waived or reimbursed
as soon as practicable after the end of the two-year period. In the event that the end of the two-year period does not coincide with the end of a fiscal year, the fees
subject to the waiver under this Letter Agreement will be calculated at the end of such fiscal year and appropriately prorated to account for the number of days during such fiscal year that this capital gains incentive fee waiver was in effect. 

This Letter Agreement shall terminate upon the earlier of (i) the waiver and/or reimbursement of all amounts due to be waived or reimbursed under this
Letter Agreement or (ii) termination of the Advisory Agreement. This Letter Agreement shall be governed by, and construed in accordance with, the laws of the State of New York; provided that nothing herein shall be construed to preempt, or to
be inconsistent with, any federal law, regulation or rule, including the Investment Company Act of 1940, as amended, and the Investment Advisers Act of 1940, as amended, and any rules and regulations promulgated thereunder. 

[Signature pages follow.] 












 
			
	Sincerely,
	
	Mount Logan Management LLC
		
	By:	 	 /s/ Ted Goldthorpe

	Name:	 	Ted Goldthorpe
	Title:	 	Authorized Signatory


 [Signature Page to Fee Waiver Letter Agreement] 













			
	ACKNOWLEDGED AND ACCEPTED
	
	Logan Ridge Finance Corporation
		
	By:	 	 /s/ Ted Goldthorpe

		
	Name:	 	Ted Goldthorpe
	Title:	 	Chief Executive Officer and President

 [Signature Page to Fee Waiver Letter Agreement]
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THE  SCHEDULE  CONTAINS  SUMMARY  FINANCIAL   INFORMATION   EXTRACTED  FROM  THE
REGISTRANTS  FIRST  QUARTER 1999  CONSOLIDATED  BALANCE  SHEET AND  CONSOLIDATED
STATEMENT  OF  OPERATIONS  FOR THE THREE  MONTHS  ENDED  MARCH  31,  1999 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-END>                               MAR-31-1999
<CASH>                                       4,063,682
<SECURITIES>                                         0
<RECEIVABLES>                               24,442,288
<ALLOWANCES>                                 3,597,116
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                       6,333,187
<DEPRECIATION>                               1,941,445
<TOTAL-ASSETS>                              54,488,175
<CURRENT-LIABILITIES>                                0
<BONDS>                                     25,548,050
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                  1,384,891
<COMMON>                                    19,867,281
<OTHER-SE>                                   4,512,148
<TOTAL-LIABILITY-AND-EQUITY>                54,488,175
<SALES>                                      5,151,509
<TOTAL-REVENUES>                             8,778,645
<CGS>                                          693,474
<TOTAL-COSTS>                                8,109,589
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                               150,846
<INTEREST-EXPENSE>                             672,281
<INCOME-PRETAX>                                 15,667
<INCOME-TAX>                                     4,000
<INCOME-CONTINUING>                              4,877
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     4,877
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0
        

</TABLE>
#### COM. v. OGUEJIOFOR, E.

27 MDA 2017

Superior Court of Pennsylvania.

09/14/2017

CP-22-SA-0000173-2016

(Dauphin)

Affirmed
AMENDMENT TO LEASE AGREEMENT
                  (Modification of terms and rents)

The purpose of this Amendment, dated January 21, 1997, is to modify 
the terms of the Lease as noted, between 2545 Central Avenue 
Partnership, "LESSOR," and Somatogen, Inc., "LESSEE," for The Premises 
located at 5797 Central Avenue, Boulder, CO.

This Amendment modifies the term of the Lease Agreement, dated 
February 14, 1995, as referenced in Paragraph 2 and all other written 
Agreements, and provides for the rent schedule Paragraph 31 and terms 
to be modified. 

The Lessor hereby leases the Premises to the Lessee, and the Lessee 
hereby leases the Premises from the Lessor, for a term commencing at 
12:01 A.M. on the 1st day of May, 1997, and ending at 11:59 P.M. on 
the 30th day of April, 2000, unless sooner terminated as herein set 
forth.  The Lessee agrees to pay Lessor as rent for the premises 
according to the terms of the RENT SCHEDULE  below:

May 1, 1997   through   April 30, 1998   $14,835.00 per month
May 1, 1998   through   April 30, 1999   $15,428.00 per month
May 1, 1999   through   April 30, 2000   $16,046.00 per month

Lessee agrees, at the request of the Lessor, to remove all equipment 
and improvements Lessee has made or added to the Premises.  
Additionally, Lessee agrees to make all the necessary repairs to the 
Premises in connection with the removal of equipment and improvements, 
in a workmanlike manner.

All other terms and conditions of the original Lease, all Amendments 
and all other written agreements are to remain in full force and 
effect.

IN WITNESS WHEREOF, the parties have hereunto set their hands and 
seals this date and year above written.

                   LESSOR:   2545 Central Avenue Partnership
                   BY:       /s/ Larry F. Frey 
                             -------------------------------

                   LESSEE:   Somatogen, Inc.
                   BY:       /s/   Timothy D. Hoogheem
                             -------------------------------
                   ITS:      Senior Vice President of Finance,
                             and Administration, CFO and Treasurer
No. 11-11135.

#### Francis *v.*United States.

C. A. 2d Cir. Certiorari denied.
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THE SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM RETAIL EQUITY
PARTNERS LIMITED PARTNERSHIP FINANCIAL STATEMENTS AS OF AND FOR THE THREE MONTHS
ENDED MARCH 31, 1999, AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                                         <C>
<PERIOD-TYPE>                                3-MOS
<FISCAL-YEAR-END>                            DEC-31-1999
<PERIOD-START>                               JAN-01-1999
<PERIOD-END>                                 MAR-31-1999
<CASH>                                         107,874
<SECURITIES>                                         0
<RECEIVABLES>                                    7,652
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               175,410
<PP&E>                                       2,865,958
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                               3,041,368
<CURRENT-LIABILITIES>                           54,456
<BONDS>                                      3,317,769
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                    (630,857)
<TOTAL-LIABILITY-AND-EQUITY>                 3,041,368
<SALES>                                              0 
<TOTAL-REVENUES>                               132,266
<CGS>                                                0
<TOTAL-COSTS>                                   20,976
<OTHER-EXPENSES>                               266,471 
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              85,158
<INCOME-PRETAX>                               (240,339)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (240,339)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (240,339)
<EPS-PRIMARY>                                    (0.71)
<EPS-DILUTED>                                    (0.71)
        


</TABLE>
# C_2023321EN.01005003.xml

| 11.9.2023 | EN | Official Journal of the European Union | C 321/50 |
| --- | --- | --- | --- |

11.9.2023

EN

Official Journal of the European Union

C 321/50

---

Order of the President of the Sixth Chamber of the Court of 15 May 2023 — European Commission v Romania

(Case C-69/22) (1)

(2023/C 321/54)

Language of the case: Romanian

The President of the Sixth Chamber has ordered that the case be removed from the register.

---

(1)  
  OJ C 171, 25.4.2022

---
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
                    The schedule contains summary financial information from the
                    Registrant's  consolidated condensed financial statements as
                    of and for the three  months  ended March 31,  1997,  and is
                    qualified in its entirety by reference to such  consolidated
                    financial statements.
</LEGEND>
<CIK>                         0000818074
<NAME>                        All AMERICAN SEMICONDUCTOR, INC.
<MULTIPLIER>                                      1,000
       
<S>                                                 <C>
<PERIOD-TYPE>                                     3-MOS
<FISCAL-YEAR-END>                               DEC-31-1997
<PERIOD-START>                                  JAN-01-1997
<PERIOD-END>                                    MAR-31-1997
<CASH>                                              204
<SECURITIES>                                          0
<RECEIVABLES>                                    37,382
<ALLOWANCES>                                      1,427
<INVENTORY>                                      68,732
<CURRENT-ASSETS>                                109,981
<PP&E>                                            9,189
<DEPRECIATION>                                    3,940
<TOTAL-ASSETS>                                  119,987
<CURRENT-LIABILITIES>                            44,358
<BONDS>                                          52,916
<PREFERRED-MANDATORY>                                 0
<PREFERRED>                                           0
<COMMON>                                            199
<OTHER-SE>                                       22,514
<TOTAL-LIABILITY-AND-EQUITY>                    119,987
<SALES>                                          62,239
<TOTAL-REVENUES>                                 62,239
<CGS>                                            48,099
<TOTAL-COSTS>                                    48,099
<OTHER-EXPENSES>                                 12,089
<LOSS-PROVISION>                                    324
<INTEREST-EXPENSE>                                1,197
<INCOME-PRETAX>                                     530
<INCOME-TAX>                                        228
<INCOME-CONTINUING>                                 302
<DISCONTINUED>                                        0
<EXTRAORDINARY>                                       0
<CHANGES>                                             0
<NET-INCOME>                                        302
<EPS-PRIMARY>                                       .02
<EPS-DILUTED>                                       .02
        


</TABLE>
No. 11-10503.

#### Jackson *v.*North Carolina.

Ct. App. N. C. Certiorari denied.
INITIAL REVIEW EXPOSUR EREPORT P-03-0104 Page 1 of:

Assessor: J Search ( )Y Focus Date:

Health: SAT Date: 11/22/02

SAT

Eco: SAT Rep: LL

Submitter: Max.yr) ImportUse: (gy)dIipr

Analogs/Comments

Chemical Name:

Trade Name: ICAS: 

Structu re:

EPA SANITIZED Page 1 of 4
INITIAL REVIEW EXPOSURE REPORT jnalog for: P-03-0104

ANALOG DATA FORM _______

Page 3____ __

RATING PHOTO RATING Page 2

ANAEROBIC BIODEGRADATION Ultimate 3-4 [DIRECT %__90

Primary ___ INDIRECT 9

Comments:

____ [AT OX ___ Sorp 2-3

HYDROLYSIS A. OH Strip 4

(pH 7, 25 C) B. ____ j03 Rem 2

Comments: Dest 3

SORPTION TO SOIL &SEDIMENT 2-3 Ult[ 3

Comments: Prim[

MIGRATION TO GROUND WATER 2-3 PersistlBioacc

BIO COMMENT

MOL WT FORM

Structure: 

EPA SANITIZED Page 2 of 4
INITIAL REVIEW EXPOSURE REPORT P-03-0104 jPage3 of:.c

SAEINEAT ILiquid EPI ESTIMATIONS

STTE MFG ILiquid

FORMUL) % < 500 

MOL WT % < 1000 

PROPERTY Submitted ICB-CRSS Method/Ref __________

MP (C)

BP (C) 1@ 760 torr 1@760 torr

@_P_(torr) _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _

VP (to rr) 

S-H-20 (gIL) Structure m/

Log Kow1111

pH, pKa Log Koc

Light Absorption (nm)T< >290 _________Log BCE BCE

Solvent: H (atm m3Imol) ___________

HYDRO t(1/2) @ pH 7 2500 da Persistence IBioaccumulation f

Volatilization (H-20) t(1/2) River hr Lake da

AOP t(1/2) (hr) JOHI 03 TotalI

MITI L1inear Prob: Nonlinear Prob:

BIODEG L1inear Prob: Nonlinear Prob: ISurvey Ult: ISurvey Prim:

STP (% Removal) ITot IIBiod IIAdsTI AirI

REMOVAL IN WWTIPOTW % Overall 0 25 1(j: ' 75 190 1=> 99

CATEGORY

RATING 1 2 3 4

Sorption ______ 1j~ oeae strong v.strong

Stripping ____extensive moderate low e Ii ib

BidgaainRemoval unknown high moderate negligible

BiodgradtionDestruction unknown complete (:Eajri'______

Comments: 5aw ; 7 Wv t..-e' *.syi

ARBCBIODEGRADATION Ultimate <= day eeks <EZHM-L. tmn

Primary <= days =ek months >months

EPA SANITIZED Page 3 of 4
INITIAL REVIEW EXPOSURE REPORT = 1 P-03-0104 jPage of:,,:4

CATEGORY

IRATING 1 2 3 4__

ANAEROBIC BIODEGRADATION Ultimate <= days weeks 6ionths - :>mnins

Primary <= days weeks months > months

Comments:

HYDROLYSIS I YR d)A. J___ <= mins hours days =>months

(t(11/2) @ pH 7, 25 C) B. I___<= mins hours days => months

Comments:

SORPTION TO SOIL & SEDIMENT v.strong /Strong moderate low

Comments:

MIGRATION TO GROUND WATER negl slo Fmoderate rapid

Comments:

VOLATILIZATION Rivers (hr) ____ negl Jslow moderate rapid

(t(1/2) w/o sediment' Lakes (da) ____ negi Jslow Fmoderate Irapid

Comments:

PHOTOLYSIS A. Direct negi slow moderate rapid

B. Indirect negl slow moderate rapid

Comments:

ATMOSPHERIC IA. OH JO t_1/2)_h negl Jslow moderate rapid

OXIDATION B1. 03 ____ negl slow moderate rapid

Comments:

EPA SANITIZED Page 4 of 4
Submitted June 2,

reversed and remanded June 28, 2017

#### In the Matter of K. N., a Child. DEPARTMENT OF HUMAN SERVICES, *Petitioner-Respondent, v.*M. M. N., *Appellant.*In the Matter of A. N., a Child. DEPARTMENT OF HUMAN SERVICES, *Petitioner-Respondent, v.*M. M. N., *Appellant.*In the Matter of R. N., a Child. DEPARTMENT OF HUMAN SERVICES, *Petitioner-Respondent, v.*M. M. N., *Appellant.*In the Matter of E. N., a Child. DEPARTMENT OF HUMAN SERVICES, *Petitioner-Respondent, v.*
      *521M. N., aka M. M. N., *Appellant.*

*520Washington County Circuit Court

16JU06415; A164210 (Control)

16JU06416; A164211

16JU06417; A164212

Washington County Circuit Court

Washington County Circuit Court

*52116JU06939; A164213

Washington County Circuit Court

396 P3d 995

George W. Kelly filed the brief for appellant.

Ellen F. Rosenblum, Attorney General, Benjamin Gutman, Solicitor General, and Inge D. Wells, Assistant Attorney General, filed the brief for respondent.

Before Armstrong, Presiding Judge, and Tookey, Judge, and Shorr, Judge.

*522PER CURIAM

Mother appeals from a judgment establishing dependency jurisdiction over four of her children. The juvenile court appointed a guardian *ad litem*for mother, and, based on the admissions the guardian *ad litem*made on mother’s behalf, entered a judgment of jurisdiction over mother’s four children. DHS concedes that the juvenile court erred.

ORS 419B.231(4) provides:

> “A court may not appoint a guardian ad litem for a parent unless the court finds by a preponderance of the evidence presented at the hearing that:

> “(a) Due to the parent’s mental or physical disability or impairment, the parent lacks substantial capacity either to understand the nature and consequences of the proceeding or to give direction and assistance to the parent’s attorney on decisions the parent must make in the proceeding; and

> “(b) The appointment of a guardian ad litem is necessary to protect the parent’s rights in the proceeding during the period of the parent’s disability or impairment.”

DHS concedes that there is insufficient evidence in the record to support the juvenile court’s finding that mother lacked “substantial capacity either to understand the nature and consequences of the proceeding or to give direction and assistance to the parent’s attorney on decisions the parent must make in the proceeding.” *Id.*We agree and accept DHS’s concession. We also agree that, because the juvenile court erred in appointing a guardian *ad litem*for mother, the court also erred in entering a judgment of jurisdiction over the children based on the guardian *ad litem’s*admissions.

Reversed and remanded.
No. 11-10549.

#### Larson *v.*Glebe, Superintendent, Stafford Creek Corrections Center.

C. A. 9th Cir. Certiorari denied.
```

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 8905 Introduced in House (IH)]

<DOC>

116th CONGRESS
  2d Session
                                H. R. 8905

To amend the Federal Food, Drug, and Cosmetic Act to reduce the threat 
 of counterfeit drugs to the pharmaceutical supply chain, and to make 
    the pharmaceutical supply chain more robust, while ensuring the 
  authenticity, content, purity, and manufacturing location and batch 
  number of drugs (including COVID-19 therapeutics and vaccines) and 
 allowing patient verification of authenticity, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            December 8, 2020

 Mr. Van Drew introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL

 
To amend the Federal Food, Drug, and Cosmetic Act to reduce the threat 
 of counterfeit drugs to the pharmaceutical supply chain, and to make 
    the pharmaceutical supply chain more robust, while ensuring the 
  authenticity, content, purity, and manufacturing location and batch 
  number of drugs (including COVID-19 therapeutics and vaccines) and 
 allowing patient verification of authenticity, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Supply Chain Security and 
Pharmaceutical Authentication Act of 2020''.

SEC. 2. PACKAGES SUBJECT TO PHARMACEUTICAL DISTRIBUTION SUPPLY CHAIN 
              REQUIREMENTS.

    Subparagraph (B) of section 581(11) of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 360eee(11)) is amended to read as follows:
                    ``(B) Individual saleable unit.--For purposes of 
                this paragraph, an `individual saleable unit' is the 
                smallest solid oral dosage form of product, or other 
                individual solid oral dosage form of product, 
                introduced into commerce by the manufacturer or 
                repackager.''.
                                 <all>
```